



Next Generation Protein Therapeutics Summit

June 5-7, 2017
Paradise Point Resort
San Diego, CA

DRIVING CREATIVE PROTEIN ENGINEERING & DESIGN TO SUCCESSFULLY TRANSFORM PROMISING NEW MOLECULES INTO DIFFERENTIATED PRODUCTS



Scientific Advisory Committees

Next Generation Protein Therapeutics

H. Kaspar Binz, Ph.D., Vice President and Co-Founder,
Molecular Partners AG, *Switzerland*

Ulrich Brinkmann, Ph.D., Expert Scientist, Roche Pharma
Research & Early Development, Roche Innovation Center
Penzberg, *Germany*

Jennifer Cochran, Ph.D., Associate Professor of
Bioengineering and Chemical Engineering, Stanford University

Jonathan Davis, Ph.D., Principal Scientist, Protein Design,
Bristol-Myers Squibb

Fredrik Frejd, Ph.D., Chief Scientific Officer, Affibody AB,
Sweden

Dragan Grabulovski, Ph.D., Executive Officer, Grabulovski
Consulting Services GmbH, *Switzerland*

Catherine Hutchings, Ph.D., Consultant, *United Kingdom*

Tomoyuki Igawa, Ph.D., Head of Biologics Discovery, Research
Division, Chugai Pharmaceutical Co., Ltd., *Japan*

Janice Reichert, Editor-in-Chief, mAbs Journal

Paul Watt, Ph.D., CSO, Phylogica Ltd., *Australia*

K. Dane Wittrup, Ph.D., Professor, Chemical Engineering &
Biological Engineering, Massachusetts Institute of Technology

Bioconjugates: From Targets to Therapeutics

Yun Bai, Ph.D., Senior Director of CMC, Ambrx

Ho Cho, Ph.D., Executive Director, Biotherapeutics,
Celgene Corporation

Dimitar Dimitrov, Ph.D., Senior Investigator, Protein
Interactions, National Cancer Institute, NIH

Rakesh Dixit, Ph.D., Vice President, R&D, Global Safety
Assessment, MedImmune

Jagath Reddy Junutula, Ph.D., Vice President,
Cellerant Therapeutics, Inc.

Thomas Pillow, Ph.D., Scientist, ADC Team Leader,
Genentech, Inc.

Elizabeth Rainbolt, Ph.D., Senior Scientist,
BioTherapeutics Pharmaceutical Sciences,
Pfizer Inc.

Pranhitha Reddy, Ph.D, Consultant, Gene to BLA LLC

Peter Senter, Ph.D., Vice President, Chemistry,
Seattle Genetics

Oliver Thiel, Ph.D., Director, Process Development,
Amgen Inc.

Next Generation Protein Therapeutics

Bioconjugates: From Targets to Therapeutics

7:00	Registration and Coffee	
8:00	Chairperson's Remarks	Chairperson's Remarks Thomas Pillow, Ph.D., Scientist, ADC Team Leader, Genentech, Inc.
8:15	KEYNOTE PRESENTATION: Bispecific Antibodies as Drugs: Are We There Yet? Paul Carter, Ph.D., Staff Scientist and Senior Director, Antibody Engineering, Genentech, Inc.	KEYNOTE PRESENTATION: N-Terminal Protein Modification as a Strategic Way to Create Biomolecular Materials for Diverse Applications Matthew B. Francis, Ph.D., Professor of Chemistry, University of California, Berkeley 
	Creative Protein Engineering and Design Approaches	Novel Conjugation Techniques
8:45	Beyond Standard of Care: New and Biobetter DARPIn® Drugs H. Kaspar Binz, Ph.D., Vice President and Co-Founder, Molecular Partners, Switzerland	Site-Specific Conjugation with Expanded Genetic Code Feng Tian, Ph.D., Chief Scientific Officer, Ambrx Inc.
9:15	Use of Phage Display and Antibody Engineering to Identify and Affinity Optimize a Bacterial Pathogen Specific Antibody for Therapeutic Application Gang Chen, Ph.D., University of Toronto	Efficient and Selective Lysine Bioconjugations Using Surfactants   Xi Hu, Ph.D., Principal Scientist, BioProcess Research & Development, Pfizer Inc.
9:45	Networking Refreshment Break in Poster & Exhibit Hall	
10:30	The Benefits of Bispecific mAb² Antibodies Targeting EGFR and HGF   Francisca Wollerton, Ph.D., Principal Scientist, Discovery, F-star Biotechnology Ltd., United Kingdom	Topic TBD Brian McGuinness, Ph.D., Head of New Product and Business Opportunities, Crescendo Biologics, United Kingdom
11:00	Multi-Specific Antibody Formats for Targeted T-cell Activity   Sebastian Meyer, Ph.D., Vice President, Protein Engineering and CMC, Numab Innovation AG, Switzerland	Expressed Protein Ligation as Bioconjugation Platform  Alex Jacobitz, Ph.D., Postdoctoral Fellow, Synthetic and Hybrid Technologies, Amgen
11:30	Novel Pairs of Antigen Targets for the Development of Bispecific Antibody Therapeutics Eugene Zhukovsky, Ph.D., Chief Scientific Officer, Biomunex Pharmaceuticals, France	Harnessing a Catalytic Lysine Residue for the Rapid, One-Step Preparation of Homogenous Antibody-Drug Conjugates  Alex R. Nanna, Ph.D. Candidate, Graduate Student, Chemistry and Immunology, The Scripps Research Institute
12:00	TECHNOLOGY WORKSHOP: Use of Engineered Ligases to Couple Peptides and Peptide-linked Entities to Other Peptides and Proteins Edmund Rodney, Business Development Consultant, EnzyPep B.V. 	
12:30	Luncheon in Poster & Exhibit Hall	
1:40	Chairperson's Remarks	Chairperson's Remarks Jagath Reddy Junutula, Ph.D., Vice President, Cellerant Therapeutics, Inc.
	Creative Protein Engineering and Design Approaches (continued)	Advances in Linker Payload Technology
1:45	Antibody Engineering to Accelerate Antigen Clearance  Zenjiro Sampei, Ph.D., Senior Research Scientist, Biologics Discovery Department, Chugai Pharmaceutical Co., Ltd., Japan	Conjugation of Targeting Ligands to Functionalized Polymeric Nanoparticles   Roger H. Pak, Ph.D., Associate Research Fellow, BioTherapeutics Pharmaceutical R & D, Pfizer Inc.
2:15	A Simple and Robust Method for Quantification and Optimization of Gene Editing Including Differentiation of Gene Disruption and Integration Events and Efficacies Ulrich Brinkmann, Ph.D., Expert Scientist, Roche Pharma Research & Early Development, Roche Innovation Center Penzberg, Germany	Linker Optimization Leads to Better ADCs in Terms of In Vitro and In Vivo Outcome   Ying Sun, Ph.D., Associate Director, R&D, Ambrx, Inc.
2:45	Networking Refreshment Break in Poster & Exhibit Hall	
	PLENARY SESSION: Afternoon Keynote Presentations	
3:30	KEYNOTE PRESENTATION: Next Generation Protein Therapeutics for Treating Cancer Jennifer Cochran, Ph.D., Associate Professor of Bioengineering and Chemical Engineering, Stanford University	
4:15	KEYNOTE PRESENTATION: The Resolution of the CRISPR USPTO Interference Proceeding Catherine Coombes, Senior Patent Attorney, HGF Limited, United Kingdom	
5:00	Networking Reception in the Poster & Exhibit Hall	

Next Generation Protein Therapeutics

Bioconjugates:
From Targets to Therapeutics

7:00	Registration and Coffee		
8:00	Chairperson's Remarks	Chairperson's Remarks Ho Cho, Ph.D., Executive Director, Biotherapeutics, Celgene Corporation	
	Advances in Immuno-Oncology	Advances in Linker Payload Technology	
8:15	Beyond FC Engineering - Improving the Properties, Effectiveness and Functionality of the Molecule Laurence Fayadat-Dilman, Ph.D., Director, Protein Sciences, Merck Research Laboratories	Novel Linkers for Antibody-Drug Conjugates Treating Cancer and Infectious Disease Thomas H. Pillow, Ph.D., Senior Scientist, Discovery Chemistry, Genentech, Inc. NEW DATA	
8:45	ADAPTIR™ Bispecifics, a Novel Platform for Development of Immuno-Oncology Therapeutics David Bienvenue, Ph.D., Senior Director, Protein Sciences, Aptevo Therapeutics NEW DATA	XTEN™ Drug Linkers Achieve High Drug Loads and Limit Exposure of Healthy Tissues Volker Schellenberger, Ph.D., CEO and President, Discovery, Amunix NEW DATA	
9:15	Antibody-Cytokine Fusion Proteins and Their Mechanism of Action Tim Fugmann, Ph.D., Head of Chemical Proteomics, Philochem AG, Switzerland	Building Atomically-Precise Hybrid Nanoparticles Alexander Spokoyny, Ph.D., Assistant Professor, Department of Chemistry and Biochemistry and California Nanosystems Institute(CNSI), University of California, Los Angeles NEW DATA	
9:45	Networking Refreshment Break in Poster & Exhibit Hall		
	CAR T Cell Therapies & Cellular Immunotherapies	Identifying New Targets – Oncology and Beyond	
10:30	Dual-targeting Chimeric Antigen Receptor T cells to Avoid Cancer Escape Marco Ruella, MD, Clinical Instructor; Associate Director Dr. June's Laboratory, Center for Cellular Immunotherapies, University of Pennsylvania NEW DATA	Glucocorticoid ADCs Lily Y. Moy, Ph.D., Director, Pharmacology, Merck & Co., Inc.	
11:00	Interim Phase I Clinical Trial Report: T4 Immunotherapy of Head and Neck Squamous Cell Carcinoma using Pan-ErbB Targeted CAR T-cells Sophie Papa, Ph.D., Senior Lecturer and Honorary Consultant Medical Oncologist, Cancer Studies, King's College London and Guy's and St Thomas' NHS Foundation Trust, United Kingdom	ABDURINS - A New Generation of Targeted Therapeutics Kurt R. Gehlsen, Ph.D., Vice President and Chief Scientific Officer, Research Corporation Technologies NEW DATA	
11:30	PANEL DISCUSSION: Feeding the Pipeline: How Will the Next Generation of Targets be Identified and What Challenges are Anticipated? Moderator: Catherine Hutchings, Ph.D., Independent Consultant, United Kingdom Panelists: Brian McGuinness, Ph.D., Head of New Product and Business Opportunities, Crescendo Biologics, United Kingdom Philip Tagari, Ph.D., Vice President, Research, Amgen, Inc. Hazel Jones, Ph.D., Oncology Chief Of Staff , AstraZeneca, United Kingdom (invited)	Biomarkers and Personalized Medicine Ilan "Lanny" Kirsch, Ph.D., Adaptive Biotherapeutics (invited)	
12:00	SPOTLIGHT SESSION: Title TBA Emilee Knowlton, Immunology Sales Specialist, ProImmune, Inc.	PROIMMUNE www.proimmune.com	
	LUNCHEON MODERATED ROUND-TABLE DISCUSSIONS		
12:30	Discussion #1: Tackling the Challenges of Bispecific Antibodies Moderator: Dragan Grabulovski, Ph.D., Executive Officer, Grabulovski Consulting Services GmbH, Switzerland	Discussion #2: Topic TBD Moderator: Sebastian Meyer, Ph.D., Vice President, Protein Engineering and CMC, Numab Innovation AG, Switzerland	Discussion #3: Topic TBD Moderator: Jennifer Cochran, Ph.D., Associate Professor of Bioengineering and Chemical Engineering, Stanford University
	Discussion #4: Topic TBD Moderator: Rakesh Dixit, Ph.D., Vice President, R&D, Global Safety Assessment, MedImmune	Discussion #5: Topic TBD Moderator: Elizabeth Rainbolt, Ph.D., Senior Scientist, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc.	Discussion #6: Topic TBD Moderator: Oliver Thiel, Ph.D., Director, Process Development, Amgen Inc.
1:40	Chairperson's Remarks	Chairperson's Remarks Elizabeth Rainbolt, Ph.D., Senior Scientist, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc.	
	New Formats & Novel Antibody Discovery Technologies	Development of Bioconjugate Vaccines	
1:45	Affimer Biotherapeutics: A Novel Protein Platform, the Preclinical Development and Validation of a PD-L1 Antagonist in Mouse Amrik Basran, Ph.D., Chief Scientific Officer, Avacta Life Sciences, United Kingdom CASE STUDY NEW DATA	Peptide-CRM197 Conjugate Vaccines – Considerations for Process Development Anouk Dirksen, Ph.D., Senior Principal Scientist, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc. CASE STUDY NEW DATA	
2:15	Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody Di Zhang, Ph.D., Senior Scientist, Biologics Research, Janssen, LLC NEW DATA	Synthetic Approaches to Glycoconjugate Vaccine Development Geert-Jan Boons, Ph.D., Professor, Complex Carbohydrate Research Center, The University of Georgia and Chemical Biology and Drug Discovery, Utrecht University, The Netherlands NEW DATA	
2:45	Investigating Affinity-Maturation Strategies and Reproducibility of Fluorescence-Activated Cell Sorting Using a Recombinant ADAPT Library Displayed on Staphylococci Johan Nilvebrant, Ph.D., MSc., Researcher, School of Biotechnology, Protein Technology, Royal Institute of Technology, Sweden CASE STUDY NEW DATA	Multicomponent Vaccines: Development Challenges A. Krishna Prasad, Ph.D., Director, Vaccine Research, Pfizer Inc.	
3:15	Networking Refreshment Break in Poster & Exhibit Hall		

	Next Generation Protein Therapeutics	Bioconjugates: From Targets to Therapeutics
	New Formats & Novel Antibody Discovery Technologies	Overcoming Development Challenges
3:45	Design Principles for Bispecific IgGs – Opportunities and Pitfalls of Artificial Disulfide Bonds Itai Benhar, Ph.D., Professor, Molecular Microbiology and Biotechnology, Tel-Aviv University, <i>Israel</i> 	Delivering Third Generation ADCs to the Patient – Implications for Process Development and Manufacturing Bernhard Stump, Ph.D., Head of Process Development, Bioconjugates, Lonza, <i>Switzerland</i>
4:15	The Use of Nanobody Formatting to Improve Immune-Oncology Therapeutics Carlo Boutton, Ph.D., Director of Technology, Discovery, Ablynx, <i>Belgium</i>  	Overcoming Development Challenges for Conjugated Vaccines Daniel Griffin, Ph.D., Associate Director, Manufacturing Science & Technology, Pfizer Inc.
4:45	Human Antibodies from Genetically Engineered Chickens Bill Harriman, Ph.D., Chief Science Officer, Crystal Bioscience  	PANEL DISCUSSION: What Disruptive Technologies are Being Developed and Applied to Overcome Development Challenges? <i>Moderator:</i> Pranhitha Reddy, Ph.D, Consultant, Gene to BLA LLC <i>Panelist:</i> Yun Bai, Ph.D., Senior Director, Process Development and Manufacturing, Ambrx Inc.
5:00	Networking Offsite Reception	

WEDNESDAY, JUNE 7, 2017
PLENARY SESSION: Bioconjugates - Clinical Updates & Lessons Learned

7:00	Registration and Coffee	
8:00	Chairperson's Remarks Pranhitha Reddy, Ph.D, Consultant, Gene to BLA LLC	
8:05	Novel Data from AXL-ADC Program Esther Breijl, Ph.D., Associate Director, ABS, Genmab 	
8:45	Protein-Drug Conjugates that are not Antibody-Based Dasa Lipovsek, Ph.D., Senior Principal Scientist, Molecular Discovery Technologies, Bristol-Myers Squibb	
9:15	Strategy to Advance ARX788 ADC from Development to Clinical Manufacturing and Lessons Learned for Future ADC Program at Ambrx Yun Bai, Ph.D., Senior Director, Process Development and Manufacturing, Ambrx Inc.  	
9:45	Networking Refreshment Break in Poster & Exhibit Hall	

	Next Generation Protein Therapeutics	Bioconjugates: From Targets to Therapeutics
	Delivery Technologies and Approaches	Bioconjugates - Clinical Updates & Lessons Learned
10:30	Identification of Antibodies that Target and Traffic the Blood-Brain Barrier Eric Shusta, Ph.D., Howard Curler Distinguished Professor, Chemical and Biological Engineering, University of Wisconsin, Madison	PANEL DISCUSSION: How do We Decrease Attrition Rates in the Clinic? What are the Problems? What can We Fix? What Technologies are Needed?
11:00	Functional Penetrating Phylomers (FPPs) for More Efficient Delivery of Biologics In Vivo Paula Cunningham, Ph.D., Group Leader, Bioassay Development, Phylogica, Australia	
11:30	Concurrent Technology Workshops	
12:00	Luncheon in Poster & Exhibit Hall	
1:10	Chairperson's Remarks	Chairperson's Remarks Pranhitha Reddy, Ph.D, Consultant, Gene to BLA LLC
	New Technologies for Challenging Targets	What are the Remaining Challenges and Path Forward for Bioconjugates?
1:15	Advancing Targeted Co-Stimulation with Antibody-Fusion Proteins by Introducing TNF Superfamily Members in a Single-Chain Format Oliver Seifert, Ph.D., Universität Stuttgart, Germany	Toxicity Melissa Schutten, Ph.D., Senior Scientist, Pathologist, Genentech, Inc.
1:45	OPN-305, A First In Class Toll Like Receptor (TLR) Antibody Inhibitor Martin Welschof, Ph.D., CEO, Opsona Therapeutics Ltd., Ireland	Challenges to Improvement in Therapeutic Index of ADCs in Solid Cancers Rakesh Dixit, Ph.D., Vice President, R&D, Biologics Safety Assessment, Translational Sciences, MedImmune-AstraZeneca
2:15	Therapeutic Strategies to Target Intracellular Proteins with Biologicals Stefan Dübel, Ph.D., Professor, Director, Department of Biotechnology, Technical University Braunschweig, Germany	PANEL DISCUSSION: Current Challenges and Path Forward for Bioconjugates – What are the Deterrents? Lessons learned? New Technologies?
2:45	Close of Conference	

Industry Rates	SAVE \$400 Register by April 7, 2017	SAVE \$200 Register by May 12, 2017	Standard Rate After May 12, 2017
Main Conference (Mon.-Tues.)	\$2,299	\$2,499	\$2,699
Group Rates (Send 4 or more)	SAVE \$400 Register by April 7, 2017	SAVE \$200 Register by May 12, 2017	Standard Rate After May 12, 2017
Main Conference (Mon.-Tues.)	\$1,999 per person	\$2,199 per person	\$2,399 per person
Academic/Government Rates*	Register by April 7, 2017	Register by May 12, 2017	Standard Rate After May 12, 2017
Main Conference (Mon.-Tues.)	\$799	\$899	\$999

*Academic/Government rates are extended to full-time employees of government, universities and university-affiliated hospitals only.

SHARE AND VIEW CUTTING-EDGE RESEARCH IN THE POSTER HALL

Share your company's research with other Protein Therapeutics professionals by presenting a poster during the event. Any registered attendee may present a poster. Poster fee: Industry: \$125. Academic: Free.

All registration, pricing, discount, and cancellation policies are available online at ProteinTherapeuticsEvent.com

SPONSORSHIP OPPORTUNITIES

What can you expect?

- Connect one-on-one with the scientists who would be implementing your tools to generate interest and gain insight.
- Showcase your expertise and demonstrate thought leadership to industry leaders and decision makers.
- Learn about the latest developments in the industry so you can better anticipate future needs of the market.
- Uncover new potential clients and partnership opportunities to grow your business.
- Highlight your company as a member of the community in an intimate setting to grow relationships.

Gold Sponsors:



Bronze Sponsors:



Technology Workshop & Spotlight Session Sponsors:



Conference Supporter:



Exhibitors:



Start Building a Sponsorship and Exhibit Strategy for Your Organization Today

Contact Patty Rose: +1.857.504.6689 • Patricia.Rose@knect365.com